Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Therapeutic Advances in Medical Oncology

Volumn 10, Issue , 2018, Pages

  Karachaliou, Niki ^a   Gonzalez Cao, Maria ^d   Crespo, Guillermo ^e   Drozdowskyj, Ana ^f   Aldeguer, Erika ^d   Gimenez Capitan, Ana ^d   Teixido, Cristina ^d   Molina Vila, Miguel Angel ^d   Viteri, Santiago ^d   Gil, Maria De Los Llanos ^d   Algarra, Salvador Martin ^g   Perez Ruiz, Elisabeth ^h   Marquez Rodas, Ivan ⁱ   Rodriguez Abreu, Delvys ^j   Blanco, Remedios ^k   Puertolas, Teresa ^l   Royo, Maria Angeles ^m   Rosell, Rafael ^b,c,d  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c IrsiCaixa Aids Research Institute   (Spain)

^d INSTITUT UNIVERSITARI DEXEUS   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f PIVOTAL   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h HOSPITAL COSTA DEL SOL   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^k Brain   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m HOSPITAL UNIVERSITARIO DR PESET   (Spain)

more..

Author keywords

Immunotherapy; Interferon gamma; Lung cancer; Melanoma; PD 1; PD L1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR YAP1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CD8+ T LYMPHOCYTE; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MRNA EXPRESSION ASSAY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 85041378574     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834017749748     Document Type: Article

References (71)

1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
3. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
4. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
5. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
6. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
7. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-1846.
8. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76.
9. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956-965.
10. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375: 1856-1867.
11. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34: 3119-3125.
12. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapyrefractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374-1385.
13. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833.
14. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
15. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
16. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-smallcell lung cancer. N Engl J Med 2015; 372: 2018-2028.
17. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renalcell carcinoma. N Engl J Med 2015; 373: 1803-1813.
18. Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 2017; 112: 200-215.
19. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128.
20. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.
21. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199.
22. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207-211.
23. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2017; 168: 542.
24. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
25. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375: 819-829.
26. Tripathi SC, Peters HL, Taguchi A, et al. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci USA 2016; 113: E1555-E1564.
27. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015; 162: 974-986.
28. Roulois D, Loo Yau H, Singhania R, et al. DNAdemethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015; 162: 961-973.
29. Dear AE. Epigenetic modulators and the new immunotherapies. N Engl J Med 2016; 374: 684-686.
30. Liu M, Ohtani H, Zhou W, et al. Vitamin C increases viral mimicry induced by 5-aza-2’-deoxycytidine. Proc Natl Acad Sci USA 2016; 113: 10238-10244.
31. Chaib I, Karachaliou N, Pilotto S, et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. J Natl Cancer Inst 2017; 109: 1-12.
32. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-712.
33. Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017; 35: 40-47.
34. Wang G, Lu X, Dey P, et al. Targeting YAPdependent MDSC infiltration impairs tumor progression. Cancer Discov 2016; 6: 80-95.
35. Yang J, Liao X, Agarwal MK, et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007; 21: 1396-1408.
36. Schlecker E, Stojanovic A, Eisen C, et al. Tumorinfiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189: 5602-5611.
37. Paley MA, Kroy DC, Odorizzi PM, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012; 338: 1220-1225.
38. Guo J, Kim D, Gao J, et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2013; 32: 151-159.
39. Zhang J, Feng H, Zhao J, et al. IκB kinase ε is an NFATc1 kinase that inhibits T cell immune response. Cell Rep 2016; 16: 405-418.
40. Baumgart S, Chen NM, Siveke JT, et al. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov 2014; 4: 688-701.
41. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011; 17: 1160-1168.
42. Critchley-Thorne RJ, Simons DL, Yan N, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009; 106: 9010-9015.
43. Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov 2017; 7: 188-201.
44. Helmich BK and Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001; 166: 6500-6508.
45. Overacre-Delgoffe AE, Chikina M, Dadey RE, et al. Interferon-γ drives treg fragility to promote anti-tumor immunity. Cell 2017; 169: 1130.e11-1141.e11.
46. Chen H, Liakou CI, Kamat A, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009; 106: 2729-2734.
47. Bald T, Landsberg J, Lopez-Ramos D, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014; 4: 674-687.
48. Zha Z, Bucher F, Nejatfard A, et al. Interferon-γ is a master checkpoint regulator of cytokineinduced differentiation. Proc Natl Acad Sci USA 2017; 114: E6867-E6874.
49. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116.
50. Patel SP and Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847-856.
51. Santarpia M and Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015; 12: 74-78.
52. Fusi A, Festino L, Botti G, et al. PD-L1 expression as a potential predictive biomarker. Lancet Oncol 2015; 16: 1285-1287.
53. Hirsch FR, McElhinny A, Stanforth D, et al. PDL1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017; 12: 208-222.
54. Gaule P, Smithy JW, Toki M, et al. A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol 2016. DOI: 10.1001/jamaoncol.2016.3015.
55. Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017; 3: 1051-1058.
56. Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017; 16: 2598-2608.
57. Yarchoan M, Johnson BA III, Lutz ER, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017; 17: 569.
58. Textor A, Schmidt K, Kloetzel PM, et al. Correction: preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med 2017; 214: 567.
59. Liu J, Li F, Ping Y, et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget 2015; 6: 24978-24989.
60. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
61. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127-137.
62. Sharma P and Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
63. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015; 5: 915-919.
64. Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015; 33: 3001.
65. Ayers M, Lunceford J, Nebozhyn M, et al. IFNgamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017; 127: 2930-2940.
66. Higgs BW, Morehouse CA, Streicher K, et al. Abstract 1773: a baseline IFNG gene expression signature correlates with clinical outcomes in durvalumab-treated advanced NSCLC cancer patients. Cancer Res 2017; 77: 1773.
67. Prat A, Navarro A, Pare L, et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res 2017; 77: 3540-3550.
68. Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature 2017; 548: 537-542.
69. Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017; 549: 101-105.
70. Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017; 549: 106-110.
71. Reguart N, Teixido C, Gimenez-Capitan A, et al. Identification of ALK, ROS1 and RET fusions by a multiplexed mRNA-based assay in formalinfixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients. Clin Chem 2017; 63: 751-760.